Clearly, the LIM1899 cell line is dependent on the EGFR signalling pathway for proliferation in vitro (Table 1); this result is rather unexpected given that these cells harbour a KRAS mutation, which, in the majority of colorectal tumours, circumvents the EGF signalling pathway inhibition in the clinic.14 This evidence concerns the gene KRAS and colorectal neoplasm.